Blogs

HELIX ANNOUNCES COMPLETION OF THE SALE OF ITS RIVEX PHARMA DIVISION TO PHARMASCIENCE

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced today the completion of the previously announced sale of its Rivex Pharma division to Pharmascience Inc. (“Pharmascience”) for gross cash proceeds of $8.5 million, subject to adjustment (the “Rivex Transaction”). The […]

FY2013

HELIX ANNOUNCES SHAREHOLDER APPROVAL FOR THE SALE OF ITS RIVEX PHARMA DIVISION TO PHARMASCIENCE AND OTHER RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the “Shareholder Meeting”) was held today as scheduled. At the Shareholder Meeting, Helix received approval of 100% of the votes cast by shareholders present, […]

FY2013